Empagliflozin Targeting the Real-World Heart Failure Population

Rocha, B; Gomes, Rafael M.; Cunha, Gonçalo J.L.; Mendes, Gonçalo; Morais, Rui; Campos, Luís; Araújo, Inês; Fonseca, Cândida

doi:10.1016/j.cardfail.2019.02.002

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HHF events in EMPA-REG OUTCOME occurred in a less diverse population than is seen for real-world HHF events [27]. EMPRISE is now providing insights into HHF outcomes in a broader population with T2D, while numerous ongoing RCTs will assess SGLT2 inhibitors specifically in a HF setting [28], including in patients without T2D, and we look forward to understanding more about the impact of these agents on HF once data become available.…”

Section: Emprise In Context—where Does Rwe Fit In the Bigger Cvot Picmentioning

confidence: 99%

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

Schernthaner

Karasik

Abraitienė

et al. 2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.

show abstract

Section: Emprise In Context—where Does Rwe Fit In the Bigger Cvot Picmentioning

confidence: 99%